Literature DB >> 20368635

The delayed-start study in Parkinson disease: can't satisfy everyone.

C Warren Olanow1, O Rascol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368635     DOI: 10.1212/WNL.0b013e3181d7d94b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Disease modification in Parkinson's disease.

Authors:  Claire Henchcliffe; W Lawrence Severt
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 2.  Time to change the blind men and the elephant approach to Parkinson disease?

Authors:  Brad A Racette; Allison W Willis
Journal:  Neurology       Date:  2015-06-12       Impact factor: 9.910

Review 3.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

4.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

5.  Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.

Authors:  Mária Baranyi; Pier Francesca Porceddu; Flóra Gölöncsér; Szabina Kulcsár; Lilla Otrokocsi; Ágnes Kittel; Annalisa Pinna; Lucia Frau; Paul B Huleatt; Mui-Ling Khoo; Christina L L Chai; Petra Dunkel; Peter Mátyus; Micaela Morelli; Beáta Sperlágh
Journal:  Mol Neurodegener       Date:  2016-01-13       Impact factor: 14.195

Review 6.  A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.

Authors:  David J M McGhee; Craig W Ritchie; John P Zajicek; Carl E Counsell
Journal:  BMC Neurol       Date:  2016-06-16       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.